Continuous infusion of recombinant factor VIIa (NovoSeven®) in the treatment of a patient with Type III von-Willebrand’s disease and alloantibodies against von-Willebrand factor - Grossmann, RE; Geisen, U; Schwender, S (Thromb Haemost, 2000)
et al.